Climb Bio (CLYM)

• Market cap: $133M
• 1 day: -3.9%
• 5 days: -7.08%
• 1 month: -0.51%
• 3 months: 15.88%
• 6 months: 57.6%
• Year to date: -4.83%
• 1 year: -43.87%
• 5 years: -87.61%
• 10 years: -87.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18